New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
09:14 EDTBMRNBioMarin 1.5M share Spot Secondary priced at $79.50
The deal range was $79.10-$79.5 BofA/Merrill acted as sole book running manager for the offering.
News For BMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
07:23 EDTBMRNBioMarin price target raised to $164 from $151 at JPMorgan
JPMorgan analyst Cory Kasimov raised his price target for BioMarin to $164 saying the company "another solid quarter." The analyst sees "plenty of potential catalysts into year end" and keeps an Overweight rating on the stock.
07:21 EDTBMRNBioMarin price target raised to $160 from $140 at William Blair
Subscribe for More Information
05:37 EDTBMRNBioMarin price target raised to $168 from $163 at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer raised his price target for BioMarin to $168 following the company's Q2 results. The quarter "was fine," Schimmer tells investors. He views the December 27 FDA action date for the company's Duchenne Muscular Dystrophy treatment drisapersen as one of the "most impactful binary events in large cap biotech through yearend." Schimmer thinks BioMarin's track record gaining FDA approval for Orphan drugs combined with the unmet need and the supportive dataset bodes well for approval. His valuation now includes nearly $50 per share for drisapersen. He keeps an Overweight rating on BioMarin.
August 3, 2015
19:01 EDTBMRNOn The Fly: After Hours Movers
Subscribe for More Information
17:14 EDTBMRNBioMarin down 1.6% after reporting Q2 results
16:04 EDTBMRNBioMarin sees FY15 revenue $850M-$880M, consensus $881.62M
Subscribe for More Information
16:02 EDTBMRNBioMarin reports Q2 EPS (51c), consensus (53c)
Reports Q2 revenue $250.5M, consensus $218.16M.
14:59 EDTBMRNNotable companies reporting after market close
Subscribe for More Information
July 29, 2015
06:38 EDTBMRNBioMarin price target raised to $163 from $147 at Piper Jaffray
Subscribe for More Information
July 21, 2015
07:59 EDTBMRNBioMarin gene therapy an overhang for Baxalta, says JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use